Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: a systematic review of clinical trials
Background Acute myeloid leukemia (AML) is a hematological malignancy due to
anomalous differentiation and proliferation of hematopoietic stem cells with myeloid blast
buildup. Induction chemotherapy is considered the first line of treatment in most patients with
AML. However, targeted therapy in the form of FLT-3, IDH, BCL-2, and immune checkpoint
inhibitors, can be considered as the first line depending on their molecular profile, resistance
to chemotherapy, comorbidities, etc. This review aims to assess the tolerability and efficacy …
anomalous differentiation and proliferation of hematopoietic stem cells with myeloid blast
buildup. Induction chemotherapy is considered the first line of treatment in most patients with
AML. However, targeted therapy in the form of FLT-3, IDH, BCL-2, and immune checkpoint
inhibitors, can be considered as the first line depending on their molecular profile, resistance
to chemotherapy, comorbidities, etc. This review aims to assess the tolerability and efficacy …
以上显示的是最相近的搜索结果。 查看全部搜索结果